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DOI 10.1016/j.str.2007.10.005The Protein Data Bank (PDB) has close
to 50,000 entries at present, seven
times its size in 1997, and SwissProt
has close to 300,000, five times the
number ten years ago (http://www.
rcsb.org/pdb/static.do?p=general_
information/pdb_statistics/; http://www.
expasy.org/sprot/relnotes/relstat.html).
The gap between sequences and
structures is still huge, a factor of ten
to twenty depending on how redun-
dancy is evaluated, but it has stopped
increasing. The fast growth of the
PDB in recent years is a remarkable
achievement, and the community of
structural biologists is rightly proud of
it. These years have seen the advent
of Structural Genomics (SG), a re-
search initiative designed to cover
the field of protein structure in a coordi-
nated manner inspired by the Human
Genome Project. SG, first proposed
in 1995 by scientists of RIKEN in Ja-
pan, was formalized in Bethesda at
the end of 1998 (Sali, 1998; Terwilliger
et al., 1998). It became a reality two
years later when Japan started the
Protein 3000 program, and the Na-
tional Institute of General Medical
Sciences launched the first Protein
Structure Initiative (PSI-1) in the United
States. PSI-1, which operated seven
pilot projects, was completed in 2005
and Protein 3000 in 2006, but PSI-2
has since taken over in the United
States and Canada, whereas in Japan,
the Genome Research Center of RIKEN
is more active than ever, and the rest
of the world hosts a number of smaller
initiatives. Nearly all are relatively short
term (three to five years) projects
planned to end in 2010 or before.
Thus, we are now in the second half-
time of the SG game, and may have
a guess at what the final score will be.
SG was born within the community
of structural biologists, but more like
a foster child. It met from the startwith the skepticism and opposition of
many colleagues, and the press has
echoed some of it. The first reproach
was that it fails to produce the prom-
ised new structures (Service, 2002).
This sounded right at the end of
2002, when only a hundred entries
had been deposited at the PDB, but
the rate of structure determination
picked up and soon reached a level
where we do not hear that reproach
any more. SG centers have already
deposited over 6000 entries, and they
account for about one-fourth of all
PDB depositions made in the first six
months of 2007. Another common crit-
icism is that SG only targets ‘‘low-
hanging fruits,’’ proteins easy to obtain
and of little biological interest. A News
and Views paper that appeared in
Nature a few months before Protein
3000 was completed, aimed that criti-
cism to the Japanese program, which
has a very strong NMR component
(Cyranoski, 2006). Biological interest
is largely a matter of opinion, and the
key words ‘‘essential function’’ or
‘‘critical role’’ that we read so often in
structure reports serve only to prove
the authors’ commitment to their sub-
ject. They are irrelevant to SG targets
that are just putative gene products
at the time of their selection. Neverthe-
less, these targets are as likely as other
proteins to have an important func-
tion, and the structure often helps
identifying it. On the other hand, all
first-round SG initiatives did exclude
‘‘difficult’’ targets. Membrane proteins
and large multicomponent assemblies
that could not be overproduced with
the technology available in 2000 were
temporarily set aside. In retrospect,
that was a wise decision. The delay
has allowed methods to mature and
new initiatives now specifically target
these systems. In any case, there is
no evidence that the ‘‘low-hangingStructure 15, November 2007 ª2fruits’’ picked in 2000–2001 were eas-
ier to prepare and crystallize or solve
by NMR than the average protein in
the average structural biology labora-
tory. The rate of failure in achieving sol-
uble overexpression and producing
diffracting crystals has been as high
in SG centers as elsewhere. Whereas
the requirements of the method may
have guided the selection of small pro-
teins and protein domains for NMR
studies, it fully complied with the rule
of the game set in 1998: SG aims first
to provide experimental models for all
the domain folds in nature. This goal
is in pass of being reached by Protein
3000 and the PSI centers, but only if
we restrict ‘‘nature’’ to man and the
model organisms whose genome had
been sequenced at the time. We now
know the diversity of DNA sequences
to be much greater than was imagined
ten years ago, and can expect many
new folds to emerge from exotic vi-
ruses and outlandish microbes, or
just from collecting samples in the
sea. All biologists welcome that diver-
sity, even though it may forbid us to
complete the fold dictionary in a finite
time.
On the whole, SG has performed as
expected in terms of structure deter-
mination up to now, and we can safely
predict that it will go on doing so in
coming years. The many new struc-
tures deposited at the PDB are its
most visible product, but not neces-
sarily the most valuable. All SG initia-
tives have made method develop-
ment an essential component of their
activity, and a coordination estab-
lished from the start has allowed the
new methods to diffuse quickly. In a
small-size program like the Yeast
Structural Genomics pilot project that
we carried out in Orsay in the years
2001–2004, we could develop generic
procedures to overexpress yeast007 Elsevier Ltd All rights reserved 1347
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protein crystallization, and design a
LIMS (laboratory information manage-
ment system) for protein studies.
Other SG labs worked in parallel on
these problems and many more, and
their experience was integrated at sev-
eral levels: by the Re´seau National des
Ge´nopoles in France, the first SPINE
(Structural Proteomics In Europe) pro-
gram in the European Union, and ISGO
(International Structural Genomics
Organization) world wide. This coordi-
nated effort yielded products that are
now widely used outside SG labs,
and some have become industrial.
Presumably, the new methods and in-
struments that were developed in the
early years of SG would have come
out anyway, but SG helped to assem-
ble teams with the incentive and the
means to carry out research on meth-
odology and instrumentation, and
made it a rule that the results would
be shared. Such teams are uncommon
in academic labs, especially in biology
departments, but synchrotron radia-
tion (SR) centers do have scientists
and engineers with a keen interest in
methods, and the involvement of SR
centers world wide has certainly been
a great asset for SG initiatives. SR cen-
ters provide X-ray for crystallography,
and much more. They have experts in
robotics, data management, software
development, and with many other
skills, eager to interact with bench sci-
entists. The structural biologists in SG
labs look for generic solutions that will
apply to many proteins rather than to
one or a few, possibly very difficult, in-
dividual systems. Thus, they are natu-
ral partners for physicists who develop
faster detectors, powerful software,
and automatic crystal handling de-
vices. The close interaction of SG
and SR teams has accelerated the
development of new instruments and
methods, and has helped to make
them user friendly. The same can be
said of the interaction with bioinfor-
matics and structural computational
biology. All SG initiatives have involved
scientists in these fields, and they have
been highly productive. Bioinformatics
has proved to be an essential tool at
each step of the SG pipeline, from
the selection of targets to the analysis
of the refined structures. In counter-1348 Structure 15, November 2007 ª200part, SG has a wealth of new data
and new problems to offer, and the
possibility of interacting with experi-
mentalists. The development of spe-
cialized LIMS and databases is a direct
product of that interaction.
The present generation of SG initia-
tives (Links to SGI-2 and other SG pro-
grams are available at http://targetdb.
pdb.org/) builds on the experience
of the years 2000–2005. In Europe,
the Medical Research Council and
the Wellcome Trust support the Oxford
Protein Production Facility for the
United Kingdom academic commu-
nity, and the European Union funds
two new programs: SPINE2-Com-
plexes and 3D-Repertoire (http://
www.oppf.ox.ac.uk/OPPF/, http://www.
3drepertoire.org, http://www.spine2.
eu). The latter two target multicompo-
nent assemblies through a combined
approach of high-resolution X-ray/
NMR and medium/low resolution cryo-
electron microscopy studies. Some of
the targets are well established, high
profile systems such as RNA polymer-
ase or the exosome that degrades
mRNA, while others are putative com-
plexes just identified in systematic
tandem-affinity purification/mass spec-
trometry studies. The two EU-funded
programs integrate the expertise ac-
quired by a number of labs, including
ours, in pilot projects that were of
a much smaller scale than SGI-1 and
Protein 3000. No SG program in Europe
had been planned to go into a pro-
duction phase, except perhaps the
Protein Structure Factory in Berlin. Tar-
geting multicomponent assemblies
requires brand new procedures to be
developed for overexpression and puri-
fication, and cryo-EM, an essential tool
in structure analysis, is not likely to
become high throughput, though we
may expect to see the method and the
instruments make great progress in
coming years.
In comparison to the EU-funded
programs, which have the budget of
one of the major centers supported
by SGI-2, the US program is not only
bigger, but it covers a much broader
field. The four major centers have
highly competent teams and well-rec-
ognized leaders, and they are equip-
ped and organized to output new
X-ray or NMR structures of ‘‘classical’’7 Elsevier Ltd All rights reservedtargets at a high rate and relatively low
cost. Together with RIKEN, they will fill
the catalog of domain and single pro-
tein structures that life and health sci-
ences need to complement genome
studies in man and model organisms.
The domain structures can be used
as building blocks when modeling
into EM electron density or for pro-
tein-protein docking studies. Thus,
they will greatly help those who ana-
lyze multicomplex assemblies. Mean-
while, the specialized centers have
taken over the other function of SG ini-
tiatives: developing methods. This in-
cludes methods for overproducing
and crystallizing membrane pro-
teins—still one of the great challenges
of structural biology. In addition, PSI-2
supports large-scale protein modeling
studies based on the experimental
structures, and repositories for the
samples and the knowledge issued
from the initiative as a whole. In sum-
mary, protein structure is approached
from several points of view in parallel,
and methodology is given full weight.
Does that make SGI-2 ‘‘big science’’
as was said of Protein 3000 in Na-
ture—knowing that to most biologists,
big implies costly and possibly bad
(Cyranoski, 2006)? The term is hardly
appropriate, given that the major cen-
ters have the size and budget of a large
structural biology lab. Whether it ap-
plies to the Human Genome Project,
where most of the sequencing was
done in a few large centers, is disput-
able, but if it does, we should say
that big science is worth the money.
The quantity and quality of the scien-
tific data that the Human Genome Pro-
ject has produced have changed the
way we look at the living world, and
the technology it has developed, the
way we study it. The first half-time of
the SG game has shown that protein
structure determination can be made
efficient, and the methods that were
developed for producing and analyz-
ing soluble proteins, are now being
extended to membrane proteins
and multicomponent assemblies. The
structural data that will accumulate
during the second half-time of the
game will reveal the mechanisms of
many molecular machines and tell us
how a living cell works at an atomic
level. Meanwhile, new technology will
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Quite possibly, its most valuable appli-
cations will be found in labs outside the
SG initiatives, and then we’ll have
proved that ‘‘big’’ can help ‘‘small’’ to
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